- Takao Saito, MD, PhD
Takao Saito, MD, PhD
- Professor Emeritus, Fukuoka University
- Director, Sanko Clinic
- Specified Medical Corporation Sanko Group
- Section Editors
- Richard J Glassock, MD, MACP
Richard J Glassock, MD, MACP
- Editor-in-Chief — Nephrology
- Section Editor — Glomerular Diseases
- Emeritus Professor
- The David Geffen School of Medicine at UCLA
- Brad H Rovin, MD
Brad H Rovin, MD
- Section Editor — Glomerular Diseases
- Professor of Medicine and Pathology
- The Ohio State University College of Medicine
Lipoprotein glomerulopathy (LPG) is a unique and rare disorder of renal lipidosis that was first reported in a Japanese patient in 1989 . It is characterized by lipoprotein thrombi in glomeruli, an abnormal plasma lipoprotein profile that resembles type III hyperlipoproteinemia, and a marked increase in serum apolipoprotein E (apo E) concentrations. LPG was subsequently found to be due to mutations of the APOE gene . However, intrinsic renal factors are also involved in the pathogenesis of LPG because of the incomplete penetrance based upon many asymptomatic carriers of APOE variants [3-5].
A review of the clinical features of LPG is presented in this topic review.
Initial reports of familial cases as well as recurrence in transplanted kidneys suggested that a systemically acting genetic factor may underlie lipoprotein glomerulopathy (LPG). It was also observed that the serum apo E isoform was inconsistent with the APOE genotype among affected individuals.
These findings predicted that an uncharacterized variant(s) of the APOE gene may underlie the pathogenesis of this disorder . This was subsequently confirmed as mutations in the APOE gene have been found in all reported cases of LPG in which DNA sequencing has been performed (algorithm 1).
APOE variants — Apolipoprotein E (apo E), an essential apolipoprotein, is a major constituent of various plasma lipoproteins. Plasma lipoprotein levels are determined in part by the binding activities of apo E to the LDL receptor, LDL receptor-related protein, and VLDL receptor. Apo E is composed of 299 amino acids and has a relative molecular mass of 34kDa.
- Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis 1989; 13:148.
- Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199.
- Saito T, Oikawa S, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron 1999; 83:193.
- Toyota K, Hashimoto T, Ogino D, et al. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. J Hum Genet 2013; 58:254.
- Hu Z, Huang S, Wu Y, et al. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int 2014; 85:416.
- Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997; 8:820.
- Amatruda JM, Margolis S, Hutchins GM. Type 3 hyperlipoproteinemia with mesangial foam cells in renal glomeruli. Arch Pathol 1974; 98:51.
- Suzaki K, Kobori S, Ueno S, et al. Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990; 80:181.
- Ellis D, Orchard TJ, Lombardozzi S, et al. Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity. J Am Soc Nephrol 1995; 6:1170.
- Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med 2002; 12:67.
- Chen S, Liu ZH, Zheng JM, et al. A complete genomic analysis of the apolipoprotein E gene in Chinese patients with lipoprotein glomerulopathy. J Nephrol 2007; 20:568.
- Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999; 56:421.
- Rovin BH, Roncone D, McKinley A, et al. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med 2007; 357:2522.
- Murano T, Matsumura R, Misawa Y, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg-->Cys) from a patient with lipoprotein glomerulopathy. Metabolism 2002; 51:201.
- Foster K, Matsunaga A, Matalon R, et al. A rare cause of posttransplantation nephrotic syndrome. Am J Kidney Dis 2005; 45:1132.
- Cheung CY, Chan AO, Chan YH, et al. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. Hong Kong Med J 2009; 15:57.
- Han J, Pan Y, Chen Y, et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract 2010; 114:c260.
- Hagiwara M, Yamagata K, Matsunaga T, et al. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23:381.
- Kinomura M, Sugiyama H, Saito T, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23:751.
- Luo B, Huang F, Liu Q, et al. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol 2008; 28:347.
- Bomback AS, Song H, D'Agati VD, et al. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. Nephrol Dial Transplant 2010; 25:3442.
- Magistroni R, Bertolotti M, Furci L, et al. Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. Clin Med Insights Case Rep 2013; 6:189.
- Konishi K, Saruta T, Kuramochi S, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 1999; 83:214.
- Ando M, Sasaki J, Hua H, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 1999; 56:1317.
- Ogawa T, Maruyama K, Hattori H, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol 2000; 14:149.
- Matsunaga A, Saito T. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia. Clin Exp Nephrol 2014; 18:220.
- Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 2006; 47:539.
- Mitani A, Ishigami M, Watase K, et al. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18:531.
- Tokura T, Itano S, Kobayashi S, et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18:536.
- Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem 2000; 275:31269.
- Ishimura A, Watanabe M, Nakashima H, et al. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clin Exp Nephrol 2009; 13:430.
- Hoffmann M, Scharnagl H, Panagiotou E, et al. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 2001; 12:524.
- Janus ED, Grant S, Lintott CJ, Wardell MR. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis 1985; 57:249.
- Innerarity TL, Hui DY, Bersot TP, Mahley RW. Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions. Adv Exp Med Biol 1986; 201:273.
- Ghiselli G, Gregg RE, Zech LA, et al. Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients. Lancet 1982; 2:405.
- Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002; 82:999.
- Langheinrich AC, Kampschulte M, Scheiter F, et al. Atherosclerosis, inflammation and lipoprotein glomerulopathy in kidneys of apoE-/-/LDL-/- double knockout mice. BMC Nephrol 2010; 11:18.
- Kiener PA, Rankin BM, Davis PM, et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 1995; 15:990.
- Huang Y, Jaffa A, Koskinen S, et al. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 1999; 19:1600.
- Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194.
- Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol 2002; 13:1527.
- Miyahara Y, Nishimura S, Watanabe M, et al. Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. Clin Exp Nephrol 2012; 16:115.
- Ito K, Nakashima H, Watanabe M, et al. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. Nephrol Dial Transplant 2012; 27:3899.
- Tavori H, Fan D, Giunzioni I, et al. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. J Lipid Res 2014; 55:2073.
- Saito T, Matsunaga A. Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis. Kidney Int 2014; 85:243.
- Zhang P, Matalon R, Kaplan L, et al. Lipoprotein glomerulopathy: first report in a Chinese male. Am J Kidney Dis 1994; 24:942.
- Meyrier A, Dairou F, Callard P, Mougenot B. Lipoprotein glomerulopathy: first case in a white European. Nephrol Dial Transplant 1995; 10:546.
- Mourad G, Djamali A, Turc-Baron C, Cristol JP. Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Nephrol Dial Transplant 1998; 13:1292.
- Boumendjel R, Papari M, Gonzalez M. A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. Arch Pathol Lab Med 2010; 134:279.
- Sethi S. Renal failure with intracapillary thrombi. Lipoprotein glomerulopathy. Kidney Int 2008; 73:1097.
- Pasquariello A, Pasquariello G, Innocenti M, et al. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. J Nephrol 2011; 24:381.
- Chang CF, Lin CC, Chen JY, et al. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3. Am J Kidney Dis 2003; 42:E18.
- Oikawa S, Suzuki N, Sakuma E, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 1991; 18:553.
- Hazzard WR, Porte D Jr, Bierman EL. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-beta disease (type 3 hyperlipoproteinemia). Metabolism 1972; 21:1009.
- Fredrickson DS, Morganroth J, Levy RI. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med 1975; 82:150.
- Saito T, Sato H, Oikawa S, et al. Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol 1993; 13:64.
- Saito T, Oikawa S, Sato H, et al. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int Suppl 1999; 71:S37.
- Kawanishi K, Sawada A, Ochi A, et al. Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature. Case Rep Nephrol Urol 2013; 3:128.
- Amenomori M, Haneda M, Morikawa J, et al. A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron 1994; 67:109.
- Sakatsume M, Kadomura M, Sakata I, et al. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int 2001; 59:1911.
- Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis 2003; 41:244.
- Arai T, Yamashita S, Yamane M, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis 2003; 169:293.
- Matsunaga A, Furuyama M, Hashimoto T, et al. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol 2009; 13:659.
- Xin Z, Zhihong L, Shijun L, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant 2009; 24:864.
- Atkins KL, Burman JD, Chamberlain ES, et al. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol Immunol 2008; 45:1600.
- Russi G, Furci L, Leonelli M, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report. J Med Case Rep 2009; 3:9311.
- Miyata T, Sugiyama S, Nangaku M, et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol 1999; 10:1590.
- APOE variants
- Role of other factors
- CLINICAL FEATURES
- Renal findings
- Non-renal manifestations
- Lipid and lipoprotein profiles
- Histopathologic findings
- - Light microscopy
- - Electron microscopy
- - Confirmation of lipoprotein deposits
- DIFFERENTIAL DIAGNOSIS
- Specific therapies
- Nonspecific therapy
- SOCIETY GUIDELINE LINKS
- SUMMARY AND RECOMMENDATIONS